



**Supplementary Figure S1.** Analysis of PRKAR1B-AS2 long noncoding RNA. (A) Nucleotide sequence of PRKAR1B-AS2. (B) Effect of PRKAR1B-AS2 knockdown on A2780-CP20 viability after 48, 72, and 120 h of treatment. (C) Effect of PRKAR1B-AS2 knockdown on SKOV3-TR viability after 48, 72, and 120 h of treatment.



Supplementary Figure S2. Cytotoxic effect of cisplatin (CIS) and alpelisib on A2780-CP20 and SKOV3-TR cells. (A) Effect of cisplatin on A2780-CP20 viability. (B) Effect of cisplatin on SKOV3-TR viability. (C) Effect of alpelisib on A2780-CP20 viability. (D) Effect of alpelisib on SKOV3-TR viability.



В

Group	No. of mice	Treatment	Dose
1	10	DOPC negative control siRNA (si-NC)	Si-NC: 200 μg/Kg, 2 x weekly, IV
2	10	DOPC PRKAR1B-AS2 siRNA	Si-PRKAR1B-AS2: 200 µg/Kg, 2 x weekly, IV
3	10	DOPC negative control siRNA (si-NC) + cisplatin	Cisplatin: 4mg/kg, 1 x weekly, IP
4	10	DOPC PRKAR1B-AS2 siRNA + cisplatin	Cisplatin: 4mg/kg, 1 x weekly, IP; Si-PRKAR1B-AS2 200 µg/Kg, 2 x weekly, IV

**Supplementary Figure S3.** *In vivo* **experiment.** (A) Design of the A2780-CP20 xenograft mouse models. (B) Treatment scheme for the four groups.